Neuronetics® and Success TMS Partner to Increase Patient Access to Leading Depression Treatment, NeuroStar® Advanced Therapy
Sparked by Founder
Today, Success TMS is one of the leading TMS Therapy providers in the US, treating hundreds of patients each day and every day in Alex's honor.
"The Success TMS team understands the hardship of depression firsthand. We've seen this disease in friends and loved ones and believe in the power of providing specialized care in order to maximize successful outcomes for patients," said
Under the terms of the partnership, Success TMS will offer NeuroStar Advanced Therapy TMS systems at all its locations. This partnership is expected to allow for the treatment of thousands of patients across Success TMS's clinic locations. Success TMS plans on continuing its aggressive growth by launching new clinics in both existing and new regions over the next 18 months, including four in
"Success TMS is at the forefront of exceptional patient service, fueled by a very personal connection to depression," said
For more information on both companies, visit neurostar.com and successtms.com.
About NeuroStar® Advanced Therapy
NeuroStar® Advanced Therapy is the market leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation. NeuroStar Advanced Therapy is the #1 TMS choice of doctors, and is widely available across the
NeuroStar is reimbursed by most commercial and government health plans, including
NeuroStar is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. In an NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were 4.2 times more likely to achieve remission compared to patients receiving sham treatment (P = 0.02; odds ratio = 4.05).3 The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head.
NeuroStar® is a registered trademark of
About Neuronetics
Forward-Looking Statements
Statements in the press regarding Neuronetics, Inc. (the "Company") that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as "outlook," "potential," "believe," "expect," "plan," "anticipate," "predict," "may," "will," "could," "would" and "should" as well as the negative of these terms and similar expressions. These statements include those relating to: the Company's expectations regarding the build out of and demand for its NeuroStar Advanced Therapy System, including with respect to trends in the incidence of depression, and its expectations or beliefs regarding future applications and development of the System; and any statements of assumptions underlying any of the foregoing items. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to: continued availability and adequacy of coverage and reimbursement from third-party payors for treatments using the Company's products; physician and patient demand for treatments using the Company's products; developments in respect of competing technologies and therapies for the indications that the Company's products treat, including depression; product defects; the Company's ability to obtain and maintain intellectual property protection for its technology; and developments in regulation in the United States, Japan and other applicable jurisdictions. For a discussion of these and other related risks, please refer to the Company's recent SEC filings which are available on the SEC's website at www.sec.gov. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in the Company's expectations.
1 Post A, et al.
2 Liston C, et al. Biol Psychiatry, (2014)
3 George MS, et al. Arch Gen Psychiatry, (2010)
View original content to download multimedia:http://www.prnewswire.com/news-releases/neuronetics-and-success-tms-partner-to-increase-patient-access-to-leading-depression-treatment-neurostar-advanced-therapy-300946153.html
SOURCE
Meagan Dominick, Office: 610-455-2779, mdominick@vaultcommunications.com